NCT01466192View on ClinicalTrials.gov

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Chronic Hepatitis C
Interventions
DRUG

MP-424 (generic name:Telaprevir)

750mg q8h for 12 weeks

DRUG

Ribavirin

400 - 1000 mg/day based on body weight for 24 weeks

DRUG

Peginterferon alfa-2b

1.5mcg/kg/week for 24 weeks

Trial Locations (1)

Unknown

Toranomon Hospital, Minato-ku

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY